Page last updated: 2024-11-04

sq 22536

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-(tetrahydrofuryl)adenine : A nucleoside analogue that is adenine in which the nitrogen at position 9 has been substituted by a tetrahydrofuran-2-yl group. It is an adenylate cyclase inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5270
CHEMBL ID64239
CHEBI ID90232
SCHEMBL ID896095
MeSH IDM0068776

Synonyms (96)

Synonym
MLS002153167
smr001230661
HMS3266A19
BRD-A56987319-001-03-8
nsc53339
9h-purin-6-amine, 9-(tetrahydro-2-furanyl)-
9-(tetrahydro-2-furyl)adenine
mls002667588 ,
6-amino-9-(tetrahydro-2-furyl)-9h-purine
nsc-53339
adenine, 9-(tetrahydro-2-furyl)-
9-(tetrahydrofuryl)adenine
17318-31-9
ax 100
adenine, 9-(tetrahydro-2-furanyl)-
EU-0101192
sq 22,536, >=97% (hplc), powder
BIO2_000891
BIO2_000411
HSCI1_000170
LOPAC0_001192
BSPBIO_001142
9-(tetrahydrofuryl)-adenine
NCGC00094445-03
sq 22536
KBIO2_000482
KBIO3_000883
KBIO3_000884
KBIOGR_000482
KBIOSS_000482
KBIO2_003050
KBIO2_005618
BCBCMAP01_000102
IDI1_002166
NCGC00094445-05
sq 22,536
NCGC00094445-01
NCGC00094445-04
NCGC00094445-02
9-(tetrahydro-2-furanyl)-9h-purin-6-amine
NCGC00015912-02
S-153
HMS1990J03
NCGC00015912-07
CHEMBL64239 ,
sq-22536
chebi:90232 ,
HMS1792J03
HMS1362J03
9-(tetrahydro-furan-2-yl)-9h-purin-6-ylamine
9-(tetrahydrofuran-2-yl)-9h-purin-6-amine
bdbm50009687
9-(oxolan-2-yl)purin-6-amine
HMS3263P05
CCG-205266
HMS2235P22
AKOS015998755
M02495
NCGC00015912-05
NCGC00015912-06
NCGC00015912-03
NCGC00015912-04
FT-0688572
9h-purin-6-amine,9-(tetrahydro-2-furanyl)-
LP01192
sq22536
9-thf-ade
S8283
HMS3369D08
SCHEMBL896095
NCGC00261877-01
tox21_501192
AC-32734
HMS3403J03
mfcd00210216
CS-6136
HY-100396
EX-A1263
J-010883
SR-01000075521-1
sr-01000075521
9-(oxolan-2-yl)-9h-purin-6-amine
Q27162414
sq 22536 - cas 17318-31-9
HMS3676B05
sq22536; sq 22536; sq-22,536; sq22,536; sq 22,536
BCP28072
HMS3412B05
AM20210049
BRD-A56987319-001-05-3
FS-6588
SDCCGSBI-0051159.P002
NCGC00015912-12
P10102
A881804
Q0105
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 4.6.1.1 (adenylate cyclase) inhibitorAn EC 4.6.* (P-O lyase) inhibitor that interferes with the action of enzyme adenylate cyclase (EC 4.6.1.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
oxolanesAny oxacycle having an oxolane (tetrahydrofuran) skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID1705
Chain A, CruzipainTrypanosoma cruziPotency3.98110.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency4.15280.100020.879379.4328AID488773; AID588453
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency2.68551.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.08270.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.39810.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency31.55080.006026.168889.1251AID488953; AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
neuropeptide S receptor isoform AHomo sapiens (human)Potency0.00080.015812.3113615.5000AID1461
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency1.06910.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki2.40000.00061.353610.0000AID156497
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki2.40000.00021.494010.0000AID156497
Phosphatidylinositol 4-kinase alphaHomo sapiens (human)IC50 (µMol)28.20000.28003.69007.1000AID155650
Phosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)IC50 (µMol)28.20007.10007.10007.1000AID155650
Phosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)IC50 (µMol)28.20007.10007.10007.1000AID155650
Phosphatidylinositol 4-kinase betaHomo sapiens (human)IC50 (µMol)28.20000.01832.45107.1000AID155650
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
phosphorylationPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
modulation by host of viral processPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
reorganization of cellular membranes to establish viral sites of replicationPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
endosome organizationPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
Golgi organizationPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
endosome organizationPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
Golgi organizationPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
lysosome organizationPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
receptor-mediated endocytosisPhosphatidylinositol 4-kinase betaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase betaHomo sapiens (human)
inner ear developmentPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
kinase activityPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
cadherin bindingPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
magnesium ion bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
AP-3 adaptor complex bindingPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
14-3-3 protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
cytoplasmPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
Golgi-associated vesicle membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
extracellular exosomePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase alphaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase alphaHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
endoplasmic reticulum membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
early endosome membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
trans-Golgi networkPhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)
BLOC-1 complexPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
mitochondrionPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
lysosomal membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
dendritePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
cytoplasmic vesiclePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
early endosome membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
growing cell tipPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
presynaptic membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
neuron projectionPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
neuronal cell bodyPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
perikaryonPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
membrane raftPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
trans-Golgi networkPhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
mitochondrial outer membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase betaHomo sapiens (human)
Golgi apparatusPhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase betaHomo sapiens (human)
rough endoplasmic reticulum membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID232961It is the ratio of Ki value of A1 receptor to that of A2 receptor.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
AID1765311Inhibition of human AC1 expressed in HEK293 cells assessed as remaining activity by measuring cAMP level at 30 uM relative to control2021European journal of medicinal chemistry, Oct-15, Volume: 222Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.
AID1765312Inhibition of human AC2 expressed in HEK293 cells assessed as remaining activity by measuring cAMP level at 30 uM relative to control2021European journal of medicinal chemistry, Oct-15, Volume: 222Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.
AID155654Inhibition of Phosphatidylinositol 4-kinase at the ATP binding site1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID233160Hydrophobicity index1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
AID1765313Inhibition of human AC3 expressed in HEK293 cells assessed as remaining activity by measuring cAMP level at 30 uM relative to control2021European journal of medicinal chemistry, Oct-15, Volume: 222Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.
AID1765309Inhibition of Bordetella pertussis ACT exposed to mouse J774.A1 cells assessed as inhibition of ACT-induced cAMP accumulation cells pretreated for 5 hrs measured after 30 mins followed by enzyme addition by immunoassay2021European journal of medicinal chemistry, Oct-15, Volume: 222Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID155653Binding affinity (Ki) against human phosphatidylinositol 4-kinase1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID340321Inhibition of adenylate cyclase2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID32339Binding affinity against adenosine A1 receptor in rat cortex by using [3H]- PIA as a radioligand1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
AID22829Vmax value was determined1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID156497Tested for inhibition of rat PC12 adenylate cyclase stimulation by using NECA as a radioligand1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
AID155650Inhibitory activity (IC50) against human phosphatidylinositol 4-kinase at the ATP binding site1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.
AID1765310Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability at 10 uM measured after 5 hrs by Cell TiterGlo Luminescent assay relative to control2021European journal of medicinal chemistry, Oct-15, Volume: 222Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.
AID33597Binding affinity against adenosine A2 receptor in rat striatum by using [3H]NECA as a radioligand1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID493017Wombat Data for BeliefDocking1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (8.70)18.2507
2000's4 (17.39)29.6817
2010's10 (43.48)24.3611
2020's7 (30.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.44 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]